Alnylam Pharmaceuticals (ALNY) Revenue Growth (3y) (2012 - 2026)
Alnylam Pharmaceuticals (ALNY) Revenue Growth (3y) (2012 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Revenue Growth (3y) (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
0.73% |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
- |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
122.97% |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
- |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
- |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
7.94% |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
- |
| 10 |
Alnylam Pharmaceuticals |
37.04 Bn |
34.03 Bn |
959.66 Mn |
54.05% |
| Date | Value |
|---|
| Mar 31, 2026 |
54.05% |
| Dec 31, 2025 |
48.49% |
| Sep 30, 2025 |
67.81% |
| Jun 30, 2025 |
50.98% |
| Mar 31, 2025 |
-47.99% |
| Dec 31, 2024 |
31.89% |
| Sep 30, 2024 |
38.72% |
| Jun 30, 2024 |
44.09% |
| Mar 31, 2024 |
40.68% |
| Dec 31, 2023 |
39.05% |
| Sep 30, 2023 |
81.34% |
| Jun 30, 2023 |
45.28% |
| Mar 31, 2023 |
47.51% |
| Dec 31, 2022 |
67.20% |
| Sep 30, 2022 |
55.67% |
| Jun 30, 2022 |
71.32% |
| Mar 31, 2022 |
85.72% |
| Dec 31, 2021 |
130.78% |
| Sep 30, 2021 |
349.28% |
| Jun 30, 2021 |
94.65% |
